Cell line name |
MR49C |
Synonyms |
ENZR 49C; 49CENZR |
Accession |
CVCL_RW52 |
Resource Identification Initiative |
To cite this cell line use: MR49C (RRID:CVCL_RW52) |
Comments |
Population: Caucasian. Selected for resistance to: ChEBI; CHEBI:68534; Enzalutamide (Xtandi; MDV-3100). Derived from site: Metastatic; Left supraclavicular lymph node; UBERON=UBERON_8480056. |
Sequence variations |
- Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line).
- Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line).
|
Disease |
Prostate carcinoma (NCIt: C4863) |
Species of origin |
Homo sapiens (Human)
(NCBI Taxonomy: 9606) |
Hierarchy |
Parent: CVCL_0395 (LNCaP) |
Sex of cell |
Male |
Age at sampling |
50Y |
Category |
Cancer cell line |
Publications | PubMed=25634993; DOI=10.1158/1078-0432.CCR-14-1108 Yamamoto Y., Loriot Y., Beraldi E., Zhang F., Wyatt A.W., Al Nakouzi N., Mo F., Zhou T.-Y., Kim Y., Monia B.P., MacLeod A.R., Fazli L., Wang Y.-Z., Collins C.C., Zoubeidi A., Gleave M.E. Generation 2.5 antisense oligonucleotides targeting the androgen receptor and its splice variants suppress enzalutamide-resistant prostate cancer cell growth. Clin. Cancer Res. 21:1675-1687(2015) |
Cross-references |
Cell line databases/resources |
cancercelllines; CVCL_RW52
|
Encyclopedic resources |
Wikidata; Q54906575
|
Entry history |
Entry creation | 05-Mar-2018 |
Last entry update | 05-Oct-2023 |
Version number | 10 |
---|